QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Completed · Phase 1/Phase 2
Conditions studied: Metastatic Melanoma
In brief
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 combined with cisplatin. The purpose of this study is to evaluate the safety, determine the Maximum-Tolerated Dose (MTD), and characterize the pharmacokinetic profile of ALT-801 given with cisplatin in patients who are chemotherapy naïve and have metastatic melanoma that is considered surgically incurable. The anti-tumor responses of ALT-801 with cisplatin will also be assessed in this trial.
Key facts
- Study ID
- NCT01029873
- Run by
- Altor BioScience
- People needed
- 25
- Starts
- 2010-02-01
- Expected to finish
- 2013-09-01
- Last updated by the study team
- 2016-10-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The Angeles Clinic and Research Institute — Los Angeles, California, United States
- MD Anderson Cancer Center Orlando — Orlando, Florida, United States
- Emory University — Atlanta, Georgia, United States
- Northwestern University — Chicago, Illinois, United States
- University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States
- Carolinas Medical Center-Brumenthal Cancer Center — Charlotte, North Carolina, United States
- St. Luke's Hospital and Health Network — Bethlehem, Pennsylvania, United States
- University of Washington, Seattle Cancer Care Center — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.